Under construction – not a live service
Sign in
Taking people in JapanPhase 2

Testing Brenipatide Against Placebo for Uncontrolled Asthma in Adults

Tests brenipatide at different doses against placebo in adults with moderate to severe asthma.

Plain-language title generated from the registry record
Registry title: A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

Key facts

Where
Chūōku, Habikino, Iizuka, Kagoshima, Kanazawa, Katsushika-ku, Nagoya, Narita, Okayama, Osaka, and Yokohama, JapanSee the 12 sites
Phase
Phase 2

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with asthma that is not well controlled. They must have used a prescribed asthma controller medicine for at least 12 months.

Age
18 to 75 years
Sex
All sexes can join.
Disease stage
Moderate to severe asthma that is not controlled. Asthma control questionnaire-6 (ACQ-6) score of 1.5 or more on 2 out of 3 visits before randomization.
Earlier treatment
Must have taken a doctor-prescribed asthma controller medicine for at least 12 months before screening. Must have had 1 severe asthma attack treated with systemic glucocorticoids in the last 12 months.

Main reasons for not taking part

  • Asthma caused by work (occupational asthma)
  • Another important lung disease, such as COPD, bronchiectasis, pulmonary fibrosis or emphysema
  • Conditions that look like asthma, such as vocal cord dysfunction
  • A current or recent active infection in the 30 days before screening up to randomization

Read by machine on 12 November 2026.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Source: NCT07219173, who can take part

Where in Japan

  • Tokyo-Eki Center-building ClinicChūōku, JapanContact: Arihiro Kiyosue (principal investigator)Taking people
  • Osaka Habikino Medical CenterHabikino, JapanContact: Osamu Matsuno (principal investigator)Taking people
  • Aso Iizuka HospitalIizuka, JapanContact: Kazunori Tobino (principal investigator)Taking people
  • Kagoshima University HospitalKagoshima, JapanContact: Takahiro Matsuyama (principal investigator)Taking people
  • Ishikawa Prefectural Central HospitalKanazawa, JapanContact: Yoshihiro Takeda (principal investigator)Taking people
  • Kameari Internal Medicine and Respiratory ClinicKatsushika-ku, JapanContact: HARUHIKO YANAGISAWA (principal investigator)Taking people
  • Japan Community Healthcare Organization Chukyo HospitalNagoya, JapanContact: Shuichi Asano (principal investigator)Taking people
  • International University of Health and Welfare Narita HospitalNarita, JapanContact: Yasuo To (principal investigator)Taking people
  • National Hospital Organization Okayama Medical CenterOkayama, JapanContact: Keiichi Fujiwara (principal investigator)Taking people
  • Okayama University HospitalOkayama, JapanContact: Nobuaki Miyahara (principal investigator)Taking people
  • Osaka Metropolitan University HospitalOsaka, JapanContact: Kazuhisa Asai (principal investigator)Taking people
  • Kanagawa Cardiovascular and Respiratory CenterYokohama, JapanContact: Shigeru Komatsu (principal investigator)Taking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Eli Lilly and Company
Trial code
NCT07219173
Record updated
5 November 2026
Original description
The purpose of this study is to assess the safety and efficacy of brenipatide at different dose levels compared with placebo in participants with moderate-to-severe asthma.Read full original descriptionShow less

A Phase 2, Multicenter, Randomized, Double-blind, 52-week Study, to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Uncontrolled Moderate to Severe Asthma

The purpose of this study is to assess the safety and efficacy of brenipatide at different dose levels compared with placebo in participants with moderate-to-severe asthma.

Study participation will last approximately 65 weeks, including screening, treatment, and follow-up periods.

Inclusion: Physician-diagnosed asthma who have received a physician-prescribed asthma controller medication for at least 12 months prior to screening visit; Participants must have an asthma control questionnaire-6 (ACQ-6) score of ≥1.5 on 2 out of 3 visits before randomization; History of 1 severe asthma exacerbation that led to systemic glucocorticoid treatment in the last 12 months prior to screening visit.

Exclusion: Have a current or recent acute, active infection. For at least 30 days before screening visit and up to the randomization visit; Known pre-existing, clinically important lung condition other than asthma, including but not limited to:; chronic respiratory infection; bronchiectasis; pulmonary fibrosis; allergic bronchopulmonary aspergillosis; emphysema; chronic bronchitis; eosinophilic granulomatosis with polyangiitis; chronic obstructive pulmonary disease, and; other mimics of asthma, that is, vocal cord dysfunction; Participants are excluded from the study if any of the following criteria apply:; An established diagnosis of occupational asthma.

ClinicalTrials.gov NCT07219173